DTIL NASDAQ
Precision BioSciences, Inc.
1W: +1.4%
1M: -15.3%
3M: -23.4%
YTD: +53.9%
1Y: +16.0%
3Y: -43.1%
5Y: -98.3%
$6.31
-0.02 (-0.32%)
Weekly Expected Move ±8.7%
$5
$6
$6
$7
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (28)
Precision BioSciences (NASDAQ:DTIL) Director Geno Germano Acquires 2,609 Shares of Stock
Squarepoint Ops LLC Increases Stock Holdings in Precision BioSciences, Inc. $DTIL
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
12 Health Care Stocks Moving In Monday's Intraday Session
Why Is Precision BioSciences Stock Gaining Wednesday?
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Precision BioSciences GAAP EPS of -$0.75 misses by $0.09, revenue of $10.84M beats by $6.79M
Earnings Scheduled For May 5, 2026
Here are the major earnings before the open Tuesday
Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates
Precision BioSciences Q1 2026 Earnings Preview
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Should You Buy Precision BioSciences (DTIL) After Golden Cross?
Aberdeen Group plc Purchases Shares of 2,138,603 Precision BioSciences, Inc. $DTIL
Q1 EPS Estimate for Precision BioSciences Raised by Analyst
Q1 Earnings Estimate for DTIL Issued By HC Wainwright
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates
Precision BioSciences GAAP EPS of $1.05 beats by $1.59, revenue of $34M beats by $24.93M
Earnings Scheduled For March 12, 2026
Here are the major earnings before the open Thursday
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision Biosciences: Still Swinging And Finally Drawing Blood
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025